EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV ‐3 in a Controlled Human Infection Model

Nele Goeyvaerts iD, Xavier Woot de Trixhe iD, Martine Neyens iD, Thomas N Kakuda iD, Liesbeth Van Wesenbeeck iD, Annemie Buelens iD, Freya Rasschaert iD, Anna Durbin iD, Oliver Ackaert iD

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70439 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Nele Goeyvaerts und 8 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, Beerse, Belgium. Hauptthemen laut MEDLINE: Antiviral Agents, Dengue, Dengue Virus, Models, Biological. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM). A combined population pharmacokinetic (PopPK) and viral dynamic model (VDM) was developed to estimate the prophylactic effect of mosnodenvir and to inform dose selection. The PopPK model is a two‐compartment model based on plasma pharmacokinetic data from three Phase I studies and Cohort 1 of the Phase IIa study. Mosnodenvir exposure metrics were estimated for participants receiving high, medium, or low doses. A VDM with an immune response compartment adequately described DENV‐3 RNA profiles for placebo participants and was subsequently extended by including a sigmoid E max relationship with average mosnodenvir concentration at steady state ( C avg,ss ) to capture the antiviral effect on virion production rate. Simulations supported daily and weekly mosnodenvir dosing regimens to further characterize the pharmacokinetic/pharmacodynamic relationship in Cohort 2. Based on the complete Phase IIa study data, the basic reproductive number for DENV‐3 in this CHIM was estimated at 21.7, and the typical C avg,ss required to achieve complete virus eradication was estimated to be 1,410 ng/mL. In conclusion, the combined PopPK and VDM approach effectively informed dose selection and characterized the pharmacokinetic‐antiviral activity relationship, supporting the development of mosnodenvir as a prophylactic treatment for dengue infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsDengueDengue VirusModels, BiologicalFemaleHumansMaleDose-Response Relationship, DrugHuman Challenge Trials as TopicVirus Replication

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Johnson & Johnson, Beerse, Belgium.
  • Johnson & Johnson, San Diego, California, USA.
  • John Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

ORCID-Profile: Nele Goeyvaerts, Xavier Woot de Trixhe, Martine Neyens, Thomas N Kakuda, Liesbeth Van Wesenbeeck, Annemie Buelens, Freya Rasschaert, Anna Durbin, Oliver Ackaert

Zitieren

APA

Goeyvaerts, N., de Trixhe, X. W., Neyens, M., Kakuda, T. N., Van Wesenbeeck, L., Buelens, A., Rasschaert, F., Durbin, A., & Ackaert, O. (2026). Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV ‐3 in a Controlled Human Infection Model. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70439

Vancouver

Goeyvaerts N, de Trixhe XW, Neyens M, Kakuda TN, Van Wesenbeeck L, Buelens A, et al. Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV ‐3 in a Controlled Human Infection Model. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70439

BibTeX
@article{Goeyvaerts2026,
  author = {Goeyvaerts, Nele and de Trixhe, Xavier Woot and Neyens, Martine and Kakuda, Thomas N and Van Wesenbeeck, Liesbeth and Buelens, Annemie and Rasschaert, Freya and Durbin, Anna and Ackaert, Oliver},
  title = {Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV ‐3 in a Controlled Human Infection Model},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70439}
}
Kostenlos starten →